AzTrials
AzTrials

Lumbar Spinal StenosisNCT00401518

A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis

A study testing Non-randomized ACADIA® Facet Replacement System, Randomized ACADIA® Facet Replacement System and Randomized Instrumented posterolateral fusion (PLF) in people with Lumbar Spinal Stenosis, run by Globus Medical Inc at 29 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine if the ACADIA® Facet Replacement System is effective in the treatment of spinal stenosis. The primary objective of the study is to evaluate the overall success rate of the Anatomic Facet Replacement System in patients with spinal stenosis when compared to a posterior spinal… Read more about this study

Who is it for?
Ages 21 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Lumbar Spinal Stenosis
What is being tested?
Non-randomized ACADIA® Facet Replacement System, Randomized ACADIA® Facet Replacement System and Randomized Instrumented posterolateral fusion (PLF)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
390 participants
Where
29 sitesin 2 countries
Study dates
Oct 2006to Oct 2017
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 21-85 years of age and skeletally mature;
  • Have undergone 6 months of non-operative treatment prior to surgery;
  • Lateral, lateral recess and/or central canal stenosis;
  • Disc height measuring ≥ 4 mm at the operative level;
  • Persistent leg, thigh and/or buttock symptoms,including pain,numbness, burning or tingling with a minimum leg pain score of 40mm as measured with the Visual Analogue Scale (VAS) Index;
  • A score greater than 2 on a scale of 1-5 on the Zurich Claudication Questionnaire (ZCQ) Symptom Severity (SS) Score-Candidate;
Show all 11Show fewer
  • A score greater than or equal to 2 on a scale of 1-4 on the ZCQ Physical Function (PF) Score;
  • A candidate for a decompression with full facetectomy at the operative level
  • Candidate for a posterior lumbar fusion;
  • Physically and mentally willing and able to comply evaluations;
  • Lives in the immediate area and has no plans to relocate;

Who cannot join

  • Previous surgical procedure at the operative or adjacent level except for one of the following: Micro-discectomy, laminectomy, lamino/foraminotomy, rhizotomy, IDET, and/or interspinous spacer;
  • Previous lumbar fusion or disc replacement procedure;
  • Osteoporosis;
  • greater than Grade I spondylolisthesis or retrolisthesis;
  • Spondylolisthesis at levels other than at the operative level;
  • Scoliosis of the lumbar spine (defined as more than 11 deg Cobb angle) as indicated by plain X-ray films;
Show all 22Show fewer
  • Primary diagnosis of discogenic back pain due to torn, herniated, inflamed or irritated disc or other pathology where the patient exhibits axial back pain from degenerative disc disease;
  • Acute traumatic pars fracture at the operative/adjacent level vertebral body;
  • Spinal stenosis at more than three lumbar segments;
  • Acute trauma to the lumbar spine within the last 24 months;
  • Active infection at the operative level, or a systemic infection;
  • Physically / mentally compromised;
  • Systemic disease that would affect the patient's welfare or the research study.
  • Immunologically suppressed or immunocompromised;
  • Insulin-Dependent Diabetes Mellitus (Type I Diabetes);
  • Currently undergoing long-term steroid therapy;
  • Metabolic bone disease;
  • Active malignancy: (except non-melanoma skin cancer), unless treated with no clinical signs or symptoms of the malignancy for at least 5 years;
  • Known allergy to cobalt chromium or titanium;
  • Used any investigational drug or device within the past 30 days;
  • Pending litigation related to back pain or injury;
  • Is a prisoner.

Trial locations and contacts

29 sites in 2 countries.

29 sites in 2 countries

United States28 sites
  • Abington Memorial Hospital

    Abington, Pennsylvania, 19001

  • Albany Medical Center

    Albany, New York, 12208

  • Central Texas Spine Institute

    Austin, Texas, 78731

  • Spine Group Beverly Hills

    Beverly Hills, California, 90211

  • Boulder Neurosurgical & Spine Associates

    Boulder, Colorado, 80303

  • Neuro-Spine Solutions

    Bristol, Tennessee, 37620

  • Indiana Spine Group

    Carmel, Indiana, 46032

  • Charleston Brain & Spine

    Charleston, South Carolina, 29406

  • Medical University of South Carolina

    Charleston, South Carolina, 29425

  • Carolina Neurosurgery and Spine Associates, P.C.

    Charlotte, North Carolina, 28204

  • OrthoCarolina Spine Center

    Charlotte, North Carolina, 28207

  • The Center for Sports Medicine & Orthopedics

    Chattanooga, Tennessee, 37404

  • Riverhills Healthcare

    Cincinnati, Ohio, 45242

  • Florida Spine Institute

    Clearwater, Florida, 33765

  • Spine Colorado

    Durango, Colorado, 81301

  • Fort Wayne Orthopaedics

    Fort Wayne, Indiana, 46804

  • Spine Midwest, Inc.

    Jefferson City, Missouri, 65101

  • Cedars-Sinai Spine Center

    Los Angeles, California, 90048

  • Rocky Mountain Associates (RMA) in Orthopedic Medicine

    Loveland, Colorado, 80538

  • Rubin Institute for Advanced Orthopaedics

    Owings Mills, Maryland, 21117

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania, 15212

  • Desert Orthopaedic Center

    Rancho Mirage, California, 92270

  • University of Utah

    Salt Lake City, Utah, 84108

  • Neurological Institute of Savannah and Center for Spine

    Savannah, Georgia, 31405

  • Spine Institute of Louisiana

    Shreveport, Louisiana, 71101

  • Springfield Neurological & Spine Institute

    Springfield, Missouri, 65804

  • Foundation for Orthopaedic Research and Education

    Tampa, Florida, 33637

  • UMASS Memorial Medical Center

    Worcester, Massachusetts, 01605

Other trials in United States

Puerto Rico1 site
  • University of Puerto Rico

    San Juan, 00921

Other trials in Puerto Rico

About this study

Official title: The Investigational Plan for the Evaluation of the ACADIA® Facet Replacement System

The purpose of this study is to determine if the ACADIA® Facet Replacement System is effective in the treatment of spinal stenosis. The primary objective of the study is to evaluate the overall success rate of the Anatomic Facet Replacement System in patients with spinal stenosis when compared to a posterior spinal fusion control.

Read the detailed description

Spinal Stenosis continues to be a major cause of back and leg pain. The condition is attributed to narrowing of the space around the nerves in the lumbar spine. This is often caused by the degenerative process in the spine and the facet joints. The current treatment calls for removal of bone around the affected nerve including the facet joints and fusing the posterior of the spine to ensure the segments remain stable.

The ACADIA® Facet Replacement System (AFRS) allows for an anatomic reconstruction of the facet joint after decompression and removal of the degenerated facet. Like the original facet joint, the replacement implant is designed to reproduce facet motion while restoring normal stability and motion.

The ACADIA® Facet Replacement System (AFRS) has been designed on the principals that have allowed other total joint replacement procedures to provide significant patient benefits. These guiding principals include:

  • Anatomically based implant design
  • Reproducible surgical technique
  • Elimination of pain

The ACADIA® Facet Replacement System allows the surgeon to remove the offending bone while preserving the motion of the facet joint.

This study will evaluate the outcomes of patients using the AFRS™ investigation compared to those receiving instrumented posterior fusion procedure. Patients will be required to complete study visits before the procedure and at 6 weeks, 3, 6, 12, 24 months post procedure and annually thereafter as required by FDA. Follow up visits consist of administration of questionnaires, radiographs and neurological assessment.

Being tested
Non-randomized ACADIA® Facet Replacement System, Randomized ACADIA® Facet Replacement System, Randomized Instrumented posterolateral fusion (PLF)
Keywords
Spinal Stenosis, Lumbar Spinal Stenosis, Facet Arthroplasty, Posterior Fusion, Facet Arthritis
Medical subject headings
Spinal Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non-randomized ACADIA® Facet Replacement SystemDevice

    Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis

  • Randomized ACADIA® Facet Replacement SystemDevice

    Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis

  • Randomized Instrumented posterolateral fusion (PLF)Device

    Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis

Study groups in NCT00401518
Study groupRoleWhat they receive
ACADIA®ExperimentalInvestigational surgical treatment using the ACADIA Facet Replacement system
Receives: Device: Non-randomized ACADIA® Facet Replacement System; Device: Randomized ACADIA® Facet Replacement System
Control Instrumented PLFActive comparatorControl surgical treatment using an instrumented posterolateral fusion
Receives: Device: Randomized Instrumented posterolateral fusion (PLF)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score

    Physical Function is measured on a scale of 1-4 points (lower values are considered a better outcome)

    Measured: 24 months

  2. Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Symptom Severity Score

    Symptom Severity is measured on a scale of 1-5 points (lower values are considered a better outcome)

    Measured: 24 months

  3. Number of Participants Who Maintained or Improved in Neurological Status.

    Neurological status is based on four types of measurement parameters: muscle strength, straight leg raise, sensory function, and reflexes. Each of the four parameters will be coded as Stable or Improved OR Deteriorated. Neurological assessment scores must be stable or improved compared with the preoperative baseline to be considered "Stable or Improved" neurological status. If these scores have deteriorated as compared to the preoperative baseline, then the neurological status is considered "Deteriorated".

    Measured: 24 months

Secondary outcomes (4)
  1. Mean Visual Analog Scale (VAS) Right Leg Pain

    The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with "no pain" on the left border and "as severe as it could be" on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.

    Measured: 24 months

  2. Mean Visual Analog Scale (VAS) Left Leg Pain

    The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with "no pain" on the left border and "as severe as it could be" on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.

    Measured: 24 months

  3. Mean Visual Analog Scale (VAS) Back Pain

    The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with "no pain" on the left border and "as severe as it could be" on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.

    Measured: 24 months

  4. Number of Participants With a Change of at Least 15 Points in Pain/Disability Using the Oswestry Disability Index (ODI) Score at 24 Months Compared With the Score at Baseline

    The Oswestry Disability Index (ODI) is a commonly used outcome-measure questionnaire for low back pain in a hospital setting. It is a self-administered questionnaire divided into ten sections designed to assess limitations of various activities of daily living. Each section is scored on a 0-5 scale, 5 representing the greatest disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2006 (estimated)
  2. Study startOct 2006
  3. Primary completionAug 2017
  4. Study completionOct 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
390 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00401518
Sponsor's protocol ID
1020-9052
Status last verified
Aug 2020
First submitted
17 Nov 2006
Last updated
10 Sep 2020
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Non-randomized ACADIA® Facet Replacement System, Randomized ACADIA® Facet Replacement System and Randomized Instrumented posterolateral fusion (PLF) in people with Lumbar Spinal Stenosis, run by Globus Medical Inc at 29 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 29 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Sep 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score (time frame: 24 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in